Advanced Therapy Medicinal Products CDMO Market: Current Analysis and Forecast (2022-2028)

Advanced Therapy Medicinal Products CDMO Market: Current Analysis and Forecast (2022-2028)

Advanced Therapy Medicinal Products (ATMPs) are a class of innovative medicinal products that include gene therapy, cell therapy, and tissue-engineered products. A CDMO, or Contract Development and Manufacturing Organization, is a company that provides services such as development, manufacturing, and quality control to support the production of ATMPs and other pharmaceutical products. The ATMP CDMO market is growing due to the increasing demand for ATMPs and the need for specialized manufacturing and development services for these complex products. As the ATMP market continues to expand, there is a high demand for CDMOs that can provide the necessary services and expertise to support the development and commercialization of ATMPs.

The Advanced Therapy Medicinal Products CDMO Market is expected to grow at a steady rate of around 14% owing to the increasing adoption of ATMPs while the demand for specialized CDMO services continues to increase. The growing demand for innovative treatments for various diseases, such as cancer and genetic disorders will drive the market growth. For instance, according to the data published by the American Cancer Society (ACS), in January 2020, around 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States.Based on product, the market is segmented into gene therapy, cell therapy, tissue engineering, and others. The gene therapy category is to witness a higher CAGR during the forecast period. This segment includes the production and manufacturing of viral and non-viral vectors for gene therapy, which are used to deliver therapeutic genes to target cells to treat various diseases. Major key players in this segment offer a range of services, including vector production, preclinical testing, and clinical trials for gene therapy products which will boost the growth of the market. For instance, in 2022, according to the American Society of Gene & Cell Therapy (ASGCT), around 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell therapies are under development.On the basis of phase, the market is categorized into phase I, phase II, phase III, and phase IV. Among these, phase I category held a significant share in the market in 2021. This is mainly due to growing R&D Initiatives and the rise in the number of advanced therapy human studies. For instance, according to the WHO, as of February 2022, around 671,228 clinical trials are ongoing globally, out of which 47,689 are under phase I clinical trials.Based on indication, the advanced therapy medicinal products CDMO market has been classified into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, and others. The oncology category is to witness higher adoption of ATMP CDMO during the forecast period. This is mainly due to the growing number of patients with various types of cancer and an increasingly elderly population. For instance, according to the World Health Organization (WHO), there were an estimated 18.1 million new cases of cancer worldwide in 2020.For a better understanding of the market adoption of the ATMP CDMO industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. this is mainly due to several factors, including the increasing demand for personalized medicine, the growing prevalence of chronic diseases, and the increasing investment in biotechnology research and development. The market is also driven by advancements in cell and gene therapy-related technologies, which are enabling the development of innovative treatments for rare diseases. For instance, as per an October 2021 update by the National Institutes of Health (NIH), USFDA, 10 pharmaceutical companies, and 5 non-profit organizations have partnered to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease.Some of the major players operating in the market include CELONIC Group; FUJIFILM Corporation; Bio Elpida; Rentschler Biopharma SE; AGC Biologics; Catalent, Inc; Lonza; WuXi AppTec Co., Ltd.; BlueReg; Thermo Fisher Scientific Inc.